Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Antibiotics
Wockhardt to launch Cefprozil, in the US, Eight FDA approval in 4 months
July 15th, 2007
Pharmaceutical and biotechnology major Wockhardt got US FDA approval for antibiotic Cefprozil tablets (250 mg and 500 mg) and is all set to launch the product in the US market. Cefprozil, a Cephalosporin class of antibiotics, is used in the treatment of Respiratory Tract and Skin infections. Wockhardt will launch Cefprozil, the generic version of brand Cefzil, sold by Bristol Myers Squibb. "Several of our products have seen a dramatic increase in market share in the US, over the last six months. Cephalosporins have been an important product in our portfolio and Cefprozil will be a good addition to this range with a market potential of around $51 million", said Wockhardt...
Source: Medical Letter on the CDC & FDA (2007-07-15)
|
